ClinicalTrials.gg
CompletedNCT04363736MARIPOSAUpdated Aug 31, 2022Results posted

A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia

A Phase 2 interventional study of Tociliuzumab in COVID-19 Pneumonia, sponsored by Hoffmann-La Roche. Completed at 24 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-31.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
97
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing tocilizumab in COVID-19 — 3 open to participants now, 4 under way, 2 of them phase 3. tocilizumab · COVID-19.

Enrollment
23rd of 38
97 · median 150
Started
2020
with 33 others
Phase 2
14 of 38
none open now
Registered
16th of 38
by date
Lead sponsor
4 of 38
Hoffmann-La Roche

Among the 38 studies testing tocilizumab in COVID-19, this one is the 23rd largest by enrollment, is one of 34 that started in 2020, is one of 14 in phase 2, and was the 16th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 38 studies testing tocilizumab in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing tocilizumab in COVID-19, or all of them as a file.
02

Study summary

This study will assess the pharmacodynamics, pharmacokinetics, safety and efficacy of two different doses of tocilizumab (TCZ) in combination with standard-of-care (SOC) in hospitalized adult participants with moderate to severe COVID-19 pneumonia.

03

Conditions studied

  • COVID-19 Pneumonia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalization with COVID-19 pneumonia confirmed by a positive polymerase chain reaction (PCR) of any specimen [e.g., respiratory, blood, urine, stool, and other bodily fluids]) and evidence of pneumonia on chest X-ray or computed tomography scan
  • For severe patients, SpO2 \</= 93% or PaO2/FiO2 \< 300 mmHg. If a participant is on supplemental oxygen with SpO2 > 93%, but desaturation \</= to 93% on lower supplemental oxygen or ambient air is documented during screening, the inclusion criterion is met
  • For moderate patients (those who do not qualify as severe based oxygen requirements), CRP > 2 x (ULN) is required
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use , as defined by the protocol
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined by the protocol

Exclusion criteria

Exclusion Criteria

  • Known severe allergic reactions to TCZ or other monoclonal antibodies
  • Active tuberculosis (TB) infection
  • Suspected active bacterial, fungal, viral, or other infection (besides SARS-CoV-2)
  • Participants who are on a mechanical ventilator > 24 hours or extracorporeal membrane oxygenation (ECMO), in shock, or combination thereof with other organ failure requiring treatment in an ICU
  • In the opinion of the investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments
  • Receipt of oral anti-rejection or immunomodulatory drugs (including TCZ) within the past 3 months
  • (ALT) or aspartate aminotransferase (AST) > 10 x detected within 24 hours at screening or at baseline (according to local laboratory reference ranges)
  • (ANC) \< 1000/uL at screening and baseline (according to local laboratory reference ranges)
  • count \< 50,000/uL at screening and baseline (according to local laboratory reference ranges)
  • Pregnancy or breastfeeding, or positive pregnancy test at a predose examination
  • Treatment with an drug within 5 drug-elimination half-lives or 30 days (whichever is longer) of randomization
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
97 participants (actual)

Study arms

  • Active comparator
    TCZ 8 mg/kg

    Participants will receive intravenous (IV) tocilizumab (TCZ) at a dose of 8 mg/kg in addition to standard-of-care treatment.

    Drug: Tociliuzumab

  • Experimental
    TCZ 4 mg/kg

    Participants will receive IV tocilizumab (TCZ) at a dose of 4 mg/kg in addition to standard-of-care treatment.

    Drug: Tociliuzumab

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Day 0-28 (AUC0-d28) of Tocilizumab)

    Time frame: Days 0-28. Participants received a second dose within 8-24 hours after the initial infusion of TCZ at the discretion of the investigator upon clinically significant demonstration of worsening signs or symptoms.

  2. Maximum Serum Concentration (Cmax) of Tocilizumab

    Time frame: Baseline - Day 60. Participants received a second dose within 8-24 hours after the initial infusion of TCZ at the discretion of the investigator upon clinically significant demonstration of worsening signs or symptoms.

  3. Clearance (CL) of Tocilizumab

    Time frame: Baseline - Day 60. Participants received a second dose within 8-24 hours after the initial infusion of TCZ at the discretion of the investigator upon clinically significant demonstration of worsening signs or symptoms.

  4. Volume of the Central Compartment (Vc) of Tocilizumab

    Time frame: Baseline - Day 60. Participants received a second dose within 8-24 hours after the initial infusion of TCZ at the discretion of the investigator upon clinically significant demonstration of worsening signs or symptoms.

  5. Serum Concentration of C-reactive Protein (CRP) Following Administration of IV TCZ

    Time frame: Baseline - Day 60

  6. Serum Concentration of Ferritin Following Administration of IV TCZ

    Time frame: Baseline - Day 60

  7. Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of IV TCZ

    Time frame: Baseline - Day 60

  8. Serum Concentration of Interleukin-6 (IL-6) Following Administration of IV TCZ

    Time frame: Baseline - Day 60

Secondary outcomes

  1. Pecentage of Participants With Adverse Events

    An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

    Time frame: Up to Day 60

  2. Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time

    Time frame: Baseline - Day 60

  3. Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity

    Time to Real-Time Polymerase Chain Reaction (RT-PCR) virus negativity was defined as the number of days from the first dose of study drug to when a negative RT-PCR SARS-CoV-2 assessment result was observed. Results are presented as a cumulative incidence function (CIF) with death as a competing risk.

    Time frame: Up to Day 28

  4. Proportion of Participants With Any Post-Treatment Infection

    Time frame: Up to Day 60

07

Results

Posted Aug 30, 2021

Participant flow

Participant flow — Overall Study
MilestoneTCZ 4 mg/kgTCZ 8 mg/kg
Started4948
Completed3035
Not completed1913
Withdrew: Withdrawal by subject10
Withdrew: Lost to follow-up107
Withdrew: Death86

Outcome measures

PrimaryArea Under the Curve From Day 0-28 (AUC0-d28) of Tocilizumab)
Time frame:
Days 0-28. Participants received a second dose within 8-24 hours after the initial infusion of TCZ at the discretion of the investigator upon clinically significant demonstration of worsening signs or symptoms.
Reported as:
Median · µg/mL*day
Area Under the Curve From Day 0-28 (AUC0-d28) of Tocilizumab)
µg/mL*dayTCZ 4 mg/kgTCZ 8 mg/kg
One dose371 (196 to 1040)849 (471 to 1500)
Two doses837 (592 to 1480)1330 (1130 to 1810)
PrimaryMaximum Serum Concentration (Cmax) of Tocilizumab
Time frame:
Baseline - Day 60. Participants received a second dose within 8-24 hours after the initial infusion of TCZ at the discretion of the investigator upon clinically significant demonstration of worsening signs or symptoms.
Reported as:
Median · µg/mL
Maximum Serum Concentration (Cmax) of Tocilizumab
µg/mLTCZ 4 mg/kgTCZ 8 mg/kg
One dose82.2 (48.8 to 134)159 (101 to 234)
Two doses150 (110 to 203)228 (198 to 363)
PrimaryClearance (CL) of Tocilizumab
Time frame:
Baseline - Day 60. Participants received a second dose within 8-24 hours after the initial infusion of TCZ at the discretion of the investigator upon clinically significant demonstration of worsening signs or symptoms.
Reported as:
Median · L/day
Clearance (CL) of Tocilizumab
L/dayTCZ 4 mg/kgTCZ 8 mg/kg
One dose0.451 (0.261 to 0.697)0.487 (0.179 to 1.16)
Two doses0.468 (0.327 to 0.701)0.629 (0.376 to 1.02)
PrimaryVolume of the Central Compartment (Vc) of Tocilizumab
Time frame:
Baseline - Day 60. Participants received a second dose within 8-24 hours after the initial infusion of TCZ at the discretion of the investigator upon clinically significant demonstration of worsening signs or symptoms.
Reported as:
Median · L
Volume of the Central Compartment (Vc) of Tocilizumab
LTCZ 4 mg/kgTCZ 8 mg/kg
One dose4.14 (2.47 to 7.11)4.34 (3.08 to 7.88)
Two doses4.2 (2.54 to 5.17)4.57 (3.59 to 7.27)
PrimarySerum Concentration of C-reactive Protein (CRP) Following Administration of IV TCZ
Time frame:
Baseline - Day 60
Reported as:
Geometric mean · mg/L
Serum Concentration of C-reactive Protein (CRP) Following Administration of IV TCZ
mg/LTCZ 4 mg/kgTCZ 8 mg/kg
Baseline125.04 ± 121.5115.77 ± 128.7
Day 1 - 15 min post-dose124.67 ± 118.8109.19 ± 134.4
Day 1 - pre-dose 2nd infusion123.49 ± 68.0118.83 ± 45.1
Day 1 - 15 min post-dose 2nd infusion116.89 ± 62.4112.97 ± 53.4
Day 2 - 24 hours post-dose85.75 ± 133.186.01 ± 124.2
Day 341.56 ± 129.639.17 ± 134.8
Day 77.27 ± 145.15.62 ± 188.3
Day 144.42 ± 554.80.87 ± 95.0
Day 213.73 ± 552.51.75 ± 1681.6
Day 283.01 ± 483.02.57 ± 2251.1
Day 352.12 ± 234.511.25 ± 1543.9
Day 602.41 ± 256.01.61 ± 154.1
PrimarySerum Concentration of Ferritin Following Administration of IV TCZ
Time frame:
Baseline - Day 60
Reported as:
Geometric mean · pmol/L
Serum Concentration of Ferritin Following Administration of IV TCZ
pmol/LTCZ 4 mg/kgTCZ 8 mg/kg
Baseline2081.46 ± 162.41821.19 ± 174.0
Day 2 - 24 hours post-dose2282.62 ± 191.31938.19 ± 154.6
Day 32016.10 ± 128.02060.41 ± 131.2
Day 71760.82 ± 170.31494.76 ± 86.7
Day 141108.34 ± 127.2720.66 ± 102.3
Day 21754.24 ± 138.4558.57 ± 119.0
Day 28393.46 ± 139.3519.51 ± 139.0
Day 35309.23 ± 105.5291.24 ± 66.5
Day 60282.85 ± 148.7246.17 ± 171.4
PrimarySerum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of IV TCZ
Time frame:
Baseline - Day 60
Reported as:
Geometric mean · ng/L
Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R) Following Administration of IV TCZ
ng/LTCZ 4 mg/kgTCZ 8 mg/kg
Baseline35869.87 ± 29.135331.04 ± 31.3
Day 1 - 15 min post-dose47037.59 ± 56.140928.43 ± 46.4
Day 2 - 15 min post-dose80880.16 ± 24.944300.00 ± NA
Day 2 - 24 hours post-dose97280.14 ± 31.390057.53 ± 28.8
Day 3139128.70 ± 26.5139528.82 ± 30.3
Day 7261637.28 ± 30.2263899.86 ± 26.7
Day 14258484.08 ± 52.3339661.18 ± 19.6
Day 21162025.68 ± 73.1265981.84 ± 49.1
Day 2882508.76 ± 102.6162795.31 ± 106.0
Day 3580425.91 ± 138.7144868.00 ± 105.4
Day 6036049.91 ± 21.734258.34 ± 22.2
PrimarySerum Concentration of Interleukin-6 (IL-6) Following Administration of IV TCZ
Time frame:
Baseline - Day 60
Reported as:
Geometric mean · ng/L
Serum Concentration of Interleukin-6 (IL-6) Following Administration of IV TCZ
ng/LTCZ 4 mg/kgTCZ 8 mg/kg
Day 1 - 15 min post-dose336.99 ± 248.8325.96 ± 236.4
Day 2 - 15 min post-dose292.69 ± 159.8638.00 ± NA
Day 2 - 24 hours post-dose733.99 ± 226.5757.17 ± 172.4
Day 3748.82 ± 394.2743.84 ± 263.0
Day 7545.44 ± 315.9589.21 ± 429.0
Day 14234.88 ± 332.2125.64 ± 345.9
Day 2149.16 ± 482.791.86 ± 465.9
Day 285.73 ± NA28.66 ± 371.7
Day 357.68 ± 361.939.79 ± 503.0
Day 602.52 ± NA2.28 ± NA
SecondaryPecentage of Participants With Adverse Events

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

Time frame:
Up to Day 60
Reported as:
Number · Percentage of Participants
Pecentage of Participants With Adverse Events
Percentage of ParticipantsTCZ 4 mg/kgTCZ 8 mg/kg
Pecentage of Participants With Adverse Events57.145.8
SecondarySevere Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time
Time frame:
Baseline - Day 60
Reported as:
Median · copies/µL
Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) (COVID-19) Viral Load Over Time
copies/µLTCZ 4 mg/kgTCZ 8 mg/kg
Baseline30.56 (0.1 to 14458.9)8.51 (0.1 to 132429.0)
Day 28.38 (0.1 to 6328.1)7.90 (0.1 to 264252.7)
Day 33.82 (0.1 to 338006.1)4.46 (0.1 to 135875.7)
Day 42.44 (0.1 to 17142.1)2.73 (0.1 to 159013.2)
Day 58.74 (0.1 to 2930.4)5.39 (0.1 to 59216.3)
Day 60.91 (0.1 to 41683.2)2.56 (0.1 to 13318.7)
Day 70.49 (0.1 to 11609.3)1.47 (0.1 to 14185.5)
Day 102.56 (0.1 to 149.3)0.59 (0.1 to 556.2)
Day 140.14 (0.1 to 26.5)0.18 (0.1 to 436.5)
Day 210.1 (0.1 to 39.6)0.12 (0.1 to 56.4)
Day 280.16 (0.1 to 3.6)0.12 (0.1 to 3.4)
Day 350.1 (0.1 to 0.2)0.12 (0.1 to 5.6)
Day 450.1 (0.1 to 0.1)0.1 (0.1 to 0.1)
Early withdrawal—0.1 (0.1 to 0.1)
Day 600.1 (0.1 to 0.1)0.1 (0.1 to 0.3)
SecondaryTime to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity

Time to Real-Time Polymerase Chain Reaction (RT-PCR) virus negativity was defined as the number of days from the first dose of study drug to when a negative RT-PCR SARS-CoV-2 assessment result was observed. Results are presented as a cumulative incidence function (CIF) with death as a competing risk.

Time frame:
Up to Day 28
Reported as:
Number · Probability
Time to Real-Time Polymerase Chain Reaction (RT-PCR) Virus Negativity
ProbabilityTCZ 4 mg/kgTCZ 8 mg/kg
CIF for event on Day 70.33890.2874
CIF for death on Day 70.06650.0000
CIF for event on Day 140.50680.5727
CIF for death on Day 140.10240.0884
CIF for event on Day 210.50680.5727
CIF for death on Day 210.14970.1280
CIF for event on Day 280.57300.6327
CIF for death on Day 280.34200.1793
SecondaryProportion of Participants With Any Post-Treatment Infection
Time frame:
Up to Day 60
Reported as:
Number · Percentage of Participants
Proportion of Participants With Any Post-Treatment Infection
Percentage of ParticipantsTCZ 4 mg/kgTCZ 8 mg/kg
COVID-19 pneumonia6.12.1
Sepsis2.04.2
Septic shock2.04.2
Pneumonia2.02.1
Urinary tract infection2.02.1
Abscess limb2.00
Atypical pneumonia2.00
Pneumonia bacterial2.00
Pneumonia klebsiella2.00
Pneumonia streptococcal2.00
Staphylococcal infection2.00

Adverse events

Collected over Up to Day 60. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TCZ 4 mg/kg8/49 (16.3%)15/49 (30.6%)4/49 (8.2%)
TCZ 8 mg/kg6/48 (12.5%)12/48 (25%)3/48 (6.3%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventTCZ 4 mg/kgTCZ 8 mg/kg
Acute kidney injuryRenal and urinary disorders1/494/48
COVID-19 pneumoniaInfections and infestations3/491/48
Septic shockInfections and infestations1/492/48
Respiratory failureRespiratory, thoracic and mediastinal disorders0/492/48
DiarrhoeaGastrointestinal disorders2/490/48
Failure to thriveMetabolism and nutrition disorders2/490/48
Disseminated intravascular coagulationBlood and lymphatic system disorders0/491/48
Cardiac failure congestiveCardiac disorders0/491/48
Cardiogenic shockCardiac disorders0/491/48
Multiple organ dysfunction syndromeGeneral disorders0/491/48
Most frequent other events
Most frequent other events
EventTCZ 4 mg/kgTCZ 8 mg/kg
HypokalaemiaMetabolism and nutrition disorders1/493/48
Alanine aminotransferase increasedInvestigations3/490/48
Aspartate aminotransferase increasedInvestigations3/490/48

Baseline characteristics

Age, Continuous
Age, Continuous(Years)TCZ 4 mg/kgTCZ 8 mg/kgTotal
Mean56.8 ± 14.359.8 ± 14.658.3 ± 14.4
Sex: Female, Male
Sex: Female, Male(Participants)TCZ 4 mg/kgTCZ 8 mg/kgTotal
Female221840
Male273057
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TCZ 4 mg/kgTCZ 8 mg/kgTotal
Hispanic or Latino111526
Not Hispanic or Latino353267
Unknown or Not Reported314
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TCZ 4 mg/kgTCZ 8 mg/kgTotal
American Indian or Alaska Native213
Asian314
Native Hawaiian or Other Pacific Islander011
Black or African American201333
White152338
More than one race101
Unknown or Not Reported8917
08

Study locations

24 sites
  • Mayo Clinic - Arizona
    Phoenix, Arizona 85054, United States
  • St. Jude Medical Center
    Fullerton, California 92835, United States
  • LAC + USC Medical Center
    Los Angeles, California 90033, United States
  • USC Keck Medical Center of USC
    Los Angeles, California 90033, United States
  • Norwalk Hospital
    Norwalk, Connecticut 06856, United States
  • Medstar Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • Advocate Christ Medical Center
    Oak Lawn, Illinois 60453, United States
  • Advocate Lutheran General Hospital
    Park Ridge, Illinois 60068, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Renown Institute for Heart & Vascular Health
    Reno, Nevada 89502, United States
  • St Joseph's Regional Medical Center
    Wayne, New Jersey 07470, United States
  • SUNY Downstate Medical Center.
    Brooklyn, New York 11203, United States
  • Jamaica Hospital Medical Center
    Jamaica, New York 11418, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Mercy St. Vincent Medical Center
    Toledo, Ohio 43608, United States
  • Lehigh Valley Health Network
    Allentown, Pennsylvania 18103, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • Allegheny Health Network (Pittsburg PA)
    Pittsburgh, Pennsylvania 15212, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • Michael E. DeBakey VA Medical Center
    Houston, Texas 77030, United States
  • Houston Methodist Sugar Land Hospital
    Sugar Land, Texas 77479, United States
09

References and documents

Publications

  • Kumar PN, Hernandez-Sanchez J, Nagel S, Feng Y, Cai F, Rabin J, Morse CG, Nadig NR, Ashraf O, Gotur DB, McComsey GA, Gafoor K, Perin P, Thornton SC, Stubbings W, Lin CJF, Tsai L. Safety and Efficacy of Tocilizumab 4 or 8 mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial. Open Forum Infect Dis. 2021 Dec 4;9(1):ofab608. doi: 10.1093/ofid/ofab608. eCollection 2022 Jan. PubMed 35024375 ↗
  • Tom J, Bao M, Tsai L, Qamra A, Summers D, Carrasco-Triguero M, McBride J, Rosenberger CM, Lin CJF, Stubbings W, Blyth KG, Carratala J, Francois B, Benfield T, Haslem D, Bonfanti P, van der Leest CH, Rohatgi N, Wiese L, Luyt CE, Kheradmand F, Rosas IO, Cai F. Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial. Crit Care Med. 2022 Mar 1;50(3):398-409. doi: 10.1097/CCM.0000000000005229. Erratum In: Crit Care Med. 2023 Aug 01;51(8):e177. doi: 10.1097/CCM.0000000000005960. PubMed 34612846 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Aug 2020, 3 months.

Results were first posted in Aug 2021, 1 year after primary completion.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 3 months is below that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2020
First posted
Apr 27, 2020
StartActual
May 5, 2020
Primary completionActual
Aug 12, 2020
CompletionActual
Aug 12, 2020
Results first posted
Aug 30, 2021
Last update
Aug 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04363736
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 27, 2020
Start date
May 5, 2020
Primary completion
Aug 12, 2020
Completion
Aug 12, 2020
Results posted
Aug 30, 2021
Last update
Aug 31, 2022

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion